Selected randomized trials in advanced Hodgkin's disease.
| Study Group (Ref) . | Patients . | Regimens . | No. of Patients . | Survival Results . | ||
|---|---|---|---|---|---|---|
. | . | . | . | FFS . | OS . | @ Years** . |
| CALGB (24) | Stages IIIA2 IIIB and IV or RT relapses | MOPP | 123 | 50% | 66% | 5 |
| MOPP alt ABVD | 23 | 65% * | 75% | 5 | ||
| ABVD | 115 | 61% * | 73% | 5 | ||
| CALGB 8952 (26) | Stage III or IV or RT relapses | ABVD | ∼428 | 65% | 87% | 3 |
| MOPP/ABV hybrid | ∼428 | 67% | 85% | 3 | ||
| INT MILAN (27) | Stage IB, IIA (bulky) | MOPP alt ABVD | 211 | 67% | 74% | 10 |
| III and IV | MOPP/ABV hybrid | 204 | 69% | 72% | 10 | |
| ECOG, CALGB, SWOG (28) | Stage IIIA2 IIIB and IV or RT relapses | MOPP/ABVD sequential | 344 | 54% | 71% | 8 |
| MOPP/ABV hybrid | 347 | 64%* | 79%* | 8 | ||
| NCI-C (29) | Stage IIIB or IV or RT relapses | MOPP alt ABVD | 148 | 67% | 83% | 5 |
| MOPP/ABV hybrid | 153 | 71% | 81% | 5 | ||
| Abbreviations: CALGB, Cancer and Acute Leukemia Group B; ECOG, Eastern Cooperative Oncology Group; SWOG, Southwest Oncology Group; NIC-C, National Cancer Institute of Canada; INT, Instituto Nazionale Tumori; FFS, failure-free survival; OS, overall survival; alt, alternating with; see text for translation of regimen acronyms | ||||||
| Study Group (Ref) . | Patients . | Regimens . | No. of Patients . | Survival Results . | ||
|---|---|---|---|---|---|---|
. | . | . | . | FFS . | OS . | @ Years** . |
| CALGB (24) | Stages IIIA2 IIIB and IV or RT relapses | MOPP | 123 | 50% | 66% | 5 |
| MOPP alt ABVD | 23 | 65% * | 75% | 5 | ||
| ABVD | 115 | 61% * | 73% | 5 | ||
| CALGB 8952 (26) | Stage III or IV or RT relapses | ABVD | ∼428 | 65% | 87% | 3 |
| MOPP/ABV hybrid | ∼428 | 67% | 85% | 3 | ||
| INT MILAN (27) | Stage IB, IIA (bulky) | MOPP alt ABVD | 211 | 67% | 74% | 10 |
| III and IV | MOPP/ABV hybrid | 204 | 69% | 72% | 10 | |
| ECOG, CALGB, SWOG (28) | Stage IIIA2 IIIB and IV or RT relapses | MOPP/ABVD sequential | 344 | 54% | 71% | 8 |
| MOPP/ABV hybrid | 347 | 64%* | 79%* | 8 | ||
| NCI-C (29) | Stage IIIB or IV or RT relapses | MOPP alt ABVD | 148 | 67% | 83% | 5 |
| MOPP/ABV hybrid | 153 | 71% | 81% | 5 | ||
| Abbreviations: CALGB, Cancer and Acute Leukemia Group B; ECOG, Eastern Cooperative Oncology Group; SWOG, Southwest Oncology Group; NIC-C, National Cancer Institute of Canada; INT, Instituto Nazionale Tumori; FFS, failure-free survival; OS, overall survival; alt, alternating with; see text for translation of regimen acronyms | ||||||